AB&B BIO-TECH-B: The application for the marketing of the quadrivalent influenza virus subunit vaccine has been approved by the National Medical Products Administration
I'm PortAI, I can summarize articles.
AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine for the population aged 6 to 35 months has been approved for market launch by the National Medical Products Administration of China. This vaccine is China's first quadrivalent influenza virus subunit vaccine for the entire population and all dosage levels, offering comprehensive protection, high-purity antigens, and a low risk of adverse reactions. The company focuses on the research and commercialization of innovative vaccines, aiming to replace traditional and imported vaccines in the Chinese market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments